Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

European Confederation of Medical Mycology (ECMM) Expert Consult - An ECMM Excellence Center Initiative.

Koehler P, Denis B, Denning D, Gangneux JP, Hoenigl M, Kontoyiannis DP, Krause R, Lagrou K, Lass-Flörl C, Maertens J, Mareković I, Meis JF, Molina JM, Pleško S, Prattes J, Rath PM, Richardson RR, Richardson M, Segal E, Seidel D, Spriet I, Steinmann J, Verweij PE, Cornely OA; European Confederation of Medical Mycology (ECMM).

Mycoses. 2020 Mar 17. doi: 10.1111/myc.13076. [Epub ahead of print]

PMID:
32181546
2.

Positive Aspergillus PCR as a marker of azole resistance or sub-therapeutic antifungal therapy in patients with chronic pulmonary aspergillosis.

Moazam S, Eades CP, Muldoon EG, Moore CB, Richardson MD, Rautemaa-Richardson R.

Mycoses. 2020 Apr;63(4):376-381. doi: 10.1111/myc.13052. Epub 2020 Feb 5.

PMID:
31981256
3.

Detecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing.

van der Torre MH, Novak-Frazer L, Rautemaa-Richardson R.

J Fungi (Basel). 2020 Jan 10;6(1). pii: E12. doi: 10.3390/jof6010012. Review.

4.

Biotic Environments Supporting the Persistence of Clinically Relevant Mucormycetes.

Richardson MD, Rautemaa-Richardson R.

J Fungi (Basel). 2019 Dec 20;6(1). pii: E4. doi: 10.3390/jof6010004. Review.

5.

The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay.

Gits-Muselli M, White PL, Mengoli C, Chen S, Crowley B, Dingemans G, Fréalle E, L Gorton R, Guiver M, Hagen F, Halliday C, Johnson G, Lagrou K, Lengerova M, Melchers WJG, Novak-Frazer L, Rautemaa-Richardson R, Scherer E, Steinmann J, Cruciani M, Barnes R, Donnelly JP, Loeffler J, Bretagne S, Alanio A.

Med Mycol. 2019 Nov 23. pii: myz115. doi: 10.1093/mmy/myz115. [Epub ahead of print]

PMID:
31758173
6.

ECMM CandiReg-A ready to use platform for outbreaks and epidemiological studies.

Koehler P, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bretagne S, Klingspor L, Lagrou K, Meis JF, Rautemaa-Richardson R, Schelenz S, Hamprecht A, Koehler FC, Kurzai O, Salmanton-García J, Vehreschild JJ, Alanio A, Alastruey-Izquierdo A, Arsic Arsenijevic V, Gangneux JP, Gow NAR, Hadina S, Hamal P, Johnson E, Klimko N, Lass-Flörl C, Mares M, Özenci V, Papp T, Roilides E, Sabino R, Segal E, Talento AF, Tortorano AM, Verweij PE, Hoenigl M, Cornely OA; European Confederation of Medical Mycology (ECMM).

Mycoses. 2019 Oct;62(10):920-927. doi: 10.1111/myc.12963. Epub 2019 Aug 1.

7.

National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice.

Schelenz S, Owens K, Guy R, Rautemaa-Richardson R, Manuel RJ, Richardson M, Moore C, Enoch DA, Micallef C, Howard P, Agrawal SG, Johnson EM, Muller-Pebody B; English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR).

J Infect. 2019 Aug;79(2):167-173. doi: 10.1016/j.jinf.2019.06.009. Epub 2019 Jun 21.

PMID:
31233810
8.

Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project.

Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, Adamkova V, Alicino C, Almyroudi MP, Atchade E, Azzini AM, Carannante N, Carnelutti A, Corcione S, Cortegiani A, Dimopoulos G, Dubler S, García-Garmendia JL, Girardis M, Cornely OA, Ianniruberto S, Kullberg BJ, Lagrou K, Le Bihan C, Luzzati R, Malbrain MLNG, Merelli M, Marques AJ, Martin-Loeches I, Mesini A, Paiva JA, Peghin M, Raineri SM, Rautemaa-Richardson R, Schouten J, Brugnaro P, Spapen H, Tasioudis P, Timsit JF, Tisa V, Tumbarello M, van den Berg CHSB, Veber B, Venditti M, Voiriot G, Wauters J, Montravers P.

Crit Care. 2019 Jun 14;23(1):219. doi: 10.1186/s13054-019-2497-3.

9.

Exposure to Aspergillus in Home and Healthcare Facilities' Water Environments: Focus on Biofilms.

Richardson M, Rautemaa-Richardson R.

Microorganisms. 2019 Jan 5;7(1). pii: E7. doi: 10.3390/microorganisms7010007. Review.

10.

Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis.

Kosmidis C, Rodriguez-Goncer I, Rautemaa-Richardson R, Richardson MD, Moore CB, Denning DW.

J Antimicrob Chemother. 2019 Apr 1;74(4):1056-1061. doi: 10.1093/jac/dky539.

PMID:
30590533
11.

Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.

Bongomin F, Maguire N, Moore CB, Felton T, Rautemaa-Richardson R.

Mycoses. 2019 Mar;62(3):217-222. doi: 10.1111/myc.12885. Epub 2019 Jan 15.

PMID:
30570179
12.

Pulmonary cryptococcosis: A review of pathobiology and clinical aspects.

Setianingrum F, Rautemaa-Richardson R, Denning DW.

Med Mycol. 2019 Feb 1;57(2):133-150. doi: 10.1093/mmy/myy086. Review.

PMID:
30329097
13.

Electrical stimulation disrupts biofilms in a human wound model and reveals the potential for monitoring treatment response with volatile biomarkers.

Ashrafi M, Novak-Frazer L, Morris J, Baguneid M, Rautemaa-Richardson R, Bayat A.

Wound Repair Regen. 2019 Jan;27(1):5-18. doi: 10.1111/wrr.12679. Epub 2018 Nov 21.

PMID:
30320423
14.

Global burden of recurrent vulvovaginal candidiasis: a systematic review.

Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R.

Lancet Infect Dis. 2018 Nov;18(11):e339-e347. doi: 10.1016/S1473-3099(18)30103-8. Epub 2018 Aug 2.

PMID:
30078662
15.

Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance.

Kean R, Delaney C, Sherry L, Borman A, Johnson EM, Richardson MD, Rautemaa-Richardson R, Williams C, Ramage G.

mSphere. 2018 Jul 11;3(4). pii: e00334-18. doi: 10.1128/mSphere.00334-18.

16.

Evaluation of risk factors for oral infection with potential for spread in a 1-year cohort study.

Färkkilä E, Rautemaa-Richardson R, Färkkilä A, Grönholm L, Lauhio A.

Clin Oral Investig. 2019 Feb;23(2):905-911. doi: 10.1007/s00784-018-2518-7. Epub 2018 Jun 14.

PMID:
29948280
17.

Validation of biofilm formation on human skin wound models and demonstration of clinically translatable bacteria-specific volatile signatures.

Ashrafi M, Novak-Frazer L, Bates M, Baguneid M, Alonso-Rasgado T, Xia G, Rautemaa-Richardson R, Bayat A.

Sci Rep. 2018 Jun 21;8(1):9431. doi: 10.1038/s41598-018-27504-z.

18.

Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors.

Simões BM, Kohler B, Clarke RB, Stringer J, Novak-Frazer L, Young K, Rautemaa-Richardson R, Zucchini G, Armstrong A, Howell SJ.

Ther Adv Med Oncol. 2018 Apr 2;10:1758835918766189. doi: 10.1177/1758835918766189. eCollection 2018.

19.

EQUAL Candida Score: An ECMM score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management.

Mellinghoff SC, Hoenigl M, Koehler P, Kumar A, Lagrou K, Lass-Flörl C, Meis JF, Menon V, Rautemaa-Richardson R, Cornely OA.

Mycoses. 2018 May;61(5):326-330. doi: 10.1111/myc.12746. Epub 2018 Feb 20.

PMID:
29325218
20.

The global problem of antifungal resistance: prevalence, mechanisms, and management.

Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A.

Lancet Infect Dis. 2017 Dec;17(12):e383-e392. doi: 10.1016/S1473-3099(17)30316-X. Epub 2017 Jul 31. Review.

PMID:
28774698

Supplemental Content

Loading ...
Support Center